Interview in Aktiespararna
NanoEcho CEO Linda Persson was recently interviewed by Aktiespararna, where she talks about NanoEcho, the next steps in our clinical programme, how our diagnostics could potentially contribute to better decision-making in healthcare, the market potential, and our ongoing rights issue. Listen to the interview in Aktiespararna’s podcast (around 30:30 in)! Watch the video interview here! NanoEcho is […]
CEO Linda Persson reflects on Q4 2025
2025 was a year characterised by a clear focus on clinical system optimisation and regulatory preparations. Disciplined cost control and prioritised resource allocation strengthened the company’s financial resilience, without compromising delivery. During the fourth quarter, clinical preparations for the next phase of the clinical programme were completed, enabling the Proof of Concept study to commence […]
Watch NanoEcho’s CEO, Linda Persson, present at Redeye’s Medtech & Diagnostics event!
During yesterday’s event, Linda presented the company, the latest developments, and the focus going forward. Watch the presentation to hear more about how NanoEcho is continuing its journey towards improved diagnostics of rectal cancer. Click here to view the presentation!
CEO Linda Persson Summarises the Third Quarter of 2025
NanoEcho’s report for the third quarter is now published — and for the first time, commercial revenues are being reported! “The quarter demonstrates steady and focused progress. During the period, we issued our first invoice to a customer while continuing to make clinical adaptations to the system ahead of the next study — a combination […]
CEO Linda Persson Summarises the First Quarter of 2025
NanoEcho’s Q2 report has now been published, and during the period several significant milestones have been achieved, strengthening the company’s position going forward. The first clinical study has been successfully completed, and alongside this, the first image of detected nanoparticles in a rectal lymph node has been published. The studies have also confirmed both the […]
NanoEcho wins tender and moves closer to its first revenues
On Thursday, 14 August, the fantastic news was announced that NanoEcho has won a public tender and has been appointed as the supplier of a research system to Lund University. The tender is a very important step towards generating the first revenues and forms part of the long-term strategy to gradually build up delivery and […]
Meet NanoEcho’s New Chairman of the Board – Björn Larsson
At the Annual General Meeting, Björn Larsson was elected as the new Chairman of the Board at NanoEcho. With an extensive background in global corporations as well as growth-stage companies within medtech, diagnostics, and precision medicine, he brings valuable leadership to the company. We asked Björn a few questions about what motivated him to join […]
NanoEcho awarded SEK 250,000 development grant
NanoEcho’s CEO, Linda Persson, together with senior software developer Martin Larsson, pitched to an expert panel appointed by Region Skåne with the aim of securing a development grant of SEK 250,000. We are now very pleased and proud to share the news that NanoEcho has been awarded the grant, which will be used to adapt […]
Significant Progress in the First Quarter of 2025
NanoEcho has published its interim report for the first quarter of 2025, highlighting several important advancements. The dose-confirmation study has been successfully completed with the primary endpoints achieved, and the collected data is now being used to optimise the system ahead of the next phase of the clinical programme. The rights issue carried out during […]
NanoEcho’s CEO and Clinical Director share more about the successfully completed study
NanoEcho’s clinical dose confirmation study has achieved its primary objectives according to the study’s design. This is a crucial milestone, indicating that the study has established an appropriate dose of the nanoparticle NEP-1 (ferumoxtran) as well as the time interval for the subsequent imaging examination. The study is the first clinical trial with NanoEcho’s imaging […]